Influence of SLC22A1 rs628031 and SLC47A1 rs2289669 genetic polymorphism on metformin response in South Indian type 2 diabetes patients – A cross-sectional study
Abstract
Metformin, an oral antidiabetic drug, is the first-line treatment for type 2 diabetes mellitus (T2DM). SLC22A1 and SLC47A1 play key roles in the transport and excretion of metformin, and genetic variations in these genes can significantly influence metformin disposition and therapeutic efficacy. The aim was to study the influence of SLC22A1 (rs628031) and SLC47A1 (rs2289669) genetic variants on the efficacy of metformin monotherapy in South Indian patients with T2DM.
The study was a cross-sectional study, conducted for 18 months. Sixty-four T2DM patients have participated in the study. Patients’ demographic characteristics were collected. Glycated hemoglobin (HbA1c) values were determined using the nephelometry technique. The genetic polymorphisms were detected using a polymerase chain reaction-restriction fragment length polymorphism technique. Bonferroni test and one-way analysis of variance were used to evaluate the statistical significance of results.
This study revealed that T2DM patients on metformin monotherapy, fasting blood sugar, postprandial blood sugar, and HbA1c values were significantly lower among those with AG genotype (103.74 ± 28.15 mg/dl, 172.76 ± 50.4 mg/dl, and 6.99% ±1.50%) of SLC22A1 (rs628031) compared to AA (154.82 ± 52.58 mg/dl, 287.45 ± 109.21 mg/dl, and 9.92% ±1.73%) or GG genotype (136.75 ± 34.76 mg/dl, 237.00 ± 62.41 mg/dl, and 10.09% ±1.08%). However, no significant differences in glycemic control were observed among the AA, AG, and GG…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.